Back to Sites

Chiangrai Prachanukroh Hospital

Site Number

5116

Address

Chiang Rai Regional Hosp. CRS
Chiangrai Prachanukroh Hospital
1039 Sathanpayaban Road
Chiang Rai, Chiang Rai 57000
Thailand

IMPAACT Members at this Site

Suree KaewPanan CAB Member

Wannipha Yenjal Clinical Research Assistant

Pra-Ornsuda Sukrakanchana CRS Coordinator

Supaporn Utsaha CRS Coordinator

Gonzague J. Jourdain CRS Leader

Pacharee Kantipong CRS Leader

Jane E. Bupp DAIDS PO

Jullapong Achalapong Investigator

Chulapong Chanta Investigator

Rawiwan Hansudewechakul Investigator

Pradthana Ounchanum Investigator

Chaiporn Kamluang Local Laboratory

Yupawan Thaweesombat Pharmacist of Record

Ruethai Wongchai Research Assistant

Sangdao Somsri Staff

Suporn Watanaporn Staff

Tim Cressey Study Coordinator

Chaniporn Yodsuwan Study Coordinator

Studies at this Site

1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)

DAIDS Number

10779

Research Area

Prevention

Study Status

Participants Off Study and Primary Analysis Completed

P1026S: PK in Pregnancy

DAIDS Number

10040

Research Area

Treatment

Study Status

Closed to Follow Up

P1083: Kaletra/Aluvia PK study

DAIDS Number

10787

Research Area

Treatment

Study Status

Concluded

P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir

DAIDS Number

11773

Research Area

Treatment

Study Status

Closed to Accrual

P1097: Raltegravir PK Study

DAIDS Number

11790

Research Area

Treatment

Study Status

Concluded

P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure

Study Status

Enrolling

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Treatment

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

34150

Research Area

Treatment

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

38504

Research Area

Treatment

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Treatment

Study Status

Enrolling